RETATRUTIDE

Is a next-generation triple agonist that simultaneously targets the GLP-1, GIP, and glucagon receptors. It offers superior appetite suppression, accelerated fat loss, and metabolic regulation beyond currently FDA-approved drugs. Clinical trials demonstrate weight-loss results that surpass both Semaglutide and Tirzepatide. The most advanced option for serious body recomposition.